ADMA

Rating buyAI MemoPost-earnings T+1

ADMA Biologics

As of 2026-08-06/Post-earnings T+1/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

high

Horizon

—

Key catalyst

Constructive Q2 results with FY2026 guidance reiterated • 2026-08-05

Expected move: +14%

Biggest risk

BIVIGAM demand, distributor ordering behavior, competitive pricing, and broader immunoglobulin-market dynamics remain execution risks. The pipeline is early, and the packet contains no confirmed analyst revisions or post-print target changes.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

The Q2 print shows ASCENIV growth accelerating while BIVIGAM stabilized, with strong profitability and reiterated FY2026 revenue guidance. Continued ASCENIV adoption, real-world evidence, and production leverage could support earnings growth and multiple recovery.

Research note

Recommendation

buy

Confidence

high

As of

2026-08-06

Base target

$12

p=55%

Bull target

$14

p=25%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ASCENIV demand momentum and BIVIGAM stabilization
ASCENIV real-world evidence and yield-enhanced production support longer-term upside
The Q2 print shows ASCENIV growth accelerating while BIVIGAM stabilized, with strong profitability and reiterated FY2026 revenue guidance.

BearKey bullets

ASCENIV growth expectations could be vulnerable to pricing, payer access, prescriber adoption, or patient-utilization variability.
BIVIGAM demand stabilization may not persist amid competitive and distributor-ordering dynamics.
SG-001 remains an early preclinical program and should not be treated as near-term value realization.

WatchKey bullets

Constructive Q2 results with FY2026 guidance reiterated

Summary

High-level snapshot

Recommendation

buy

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $12 (p=55%)

Bull/Bear spread: +39% / -25%

Vs latest close: Bull +39% · Base +14% · Bear -25%

Scenario probabilities

Bull Target: $14 (p=25%)Base Target: $12 (p=55%)Bear Target: $8 (p=20%)

Commentary

The primary earnings filing is clearly constructive, with strong ASCENIV growth, improving BIVIGAM trends, profitability growth, and reiterated guidance. However, this T+1 packet does not provide a clean post-release price reaction, analyst revision set, or usable social coverage; missing reaction and revision data are not treated as positive evidence. The thesis has improved from the prior neutral baseline, but remains an execution-monitoring view rather than a fully confirmed re-rating.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ASCENIV demand momentum and BIVIGAM stabilization
ASCENIV real-world evidence and yield-enhanced production support longer-term upside

Scenarios

Bull Target (Scenario probability)

$14 / p=25% prob

Base Target (Scenario probability)

$12 / p=55% prob

Bear Target (Scenario probability)

$8 / p=20% prob

Price $10 as of 2026-08-06

Nearest Scenario: Base (∆ 14%)

Targets vs latest close: Bull +39% · Base +14% · Bear -25%

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-05
Constructive Q2 results with FY2026 guidance reiterated
ADMA reported Q2 2026 revenue of $124.4 million, ASCENIV revenue growth of 24% year over year, adjusted EBITDA growth of 22%, and reiterated FY2026 revenue guidance of $530-$560 million. The filing supports a positive earnings-driven thesis, although consensus-comparison data is unavailable. [#SEC-8K-2026-08-05]
Prob 95.00% • Move 8.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

ASCENIV demand momentum and BIVIGAM stabilization
2026-09-30
Management cited increasing physician adoption, prescriber engagement, new patient starts, and utilization for ASCENIV, while BIVIGAM demand stabilized with sequential improvement. Persistence of these trends is the key near-term execution test. [#SEC-8K-2026-08-05]
Prob 60% • Move 6% • Priced-in 45%

Long-term Catalysts

Months to a year

ASCENIV real-world evidence and yield-enhanced production support longer-term upside
2027-08-06
ADMA reported real-world data from 127 ASCENIV-treated patients and submitted an abstract for the November 2026 ACAAI meeting. Separately, the 2025 10-K identified 2026 as the first full year of yield-enhanced production, creating a potential margin and capacity lever. [#SEC-8K-2026-08-05] [#10-K-2026-02-25]
Prob 65% • Move 14% • Priced-in 35%

Risks

ASCENIV growth expectations could be vulnerable to pricing, payer access, prescriber adoption, or patient-utilization variability.
BIVIGAM demand stabilization may not persist amid competitive and distributor-ordering dynamics.
SG-001 remains an early preclinical program and should not be treated as near-term value realization.
The November 2026 ACAAI item is only a submitted abstract; acceptance, presentation, and commercial impact are not confirmed.
The packet lacks reliable post-print analyst revisions, consensus surprise data, and a clean market-reaction read.

Peers

Symbol	Summary
HRMY	Closest market-cap candidate in the packet, but product and indication overlap with ADMA is not established; useful only as a loose commercial-biopharma reference.
SION	Same-sector market-cap candidate rather than a direct operating peer; limited support for relative valuation comparison.
SLS	Same-sector market-cap candidate with loose operating comparability; the peer set remains insufficient for a high-confidence relative valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

AI Stock Memo: ADMA - ADMA Biologics - RankAlpha